Marinus Pharmaceuticals Company Profile (NASDAQ:MRNS)

About Marinus Pharmaceuticals

Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MRNS
  • CUSIP:
Key Metrics:
  • Previous Close: $1.37
  • 50 Day Moving Average: $1.25
  • 200 Day Moving Average: $1.33
  • 52-Week Range: $0.82 - $6.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.13
  • P/E Growth: 0.00
  • Market Cap: $27.00M
  • Outstanding Shares: 19,705,000
  • Beta: 2.08
Profitability:
  • Return on Equity: -79.45%
  • Return on Assets: -60.04%
Debt:
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 4.04%
  • Quick Ratio: 4.04%
Additional Links:
Companies Related to Marinus Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Marinus Pharmaceuticals (NASDAQ:MRNS) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $9.50 (593.43% upside)

Analysts' Ratings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Show:
DateFirmActionRatingPrice TargetDetails
10/3/2016Jefferies Group LLCReiterated RatingBuy$3.00View Rating Details
6/28/2016Stifel NicolausReiterated RatingHoldView Rating Details
6/14/2016Goldman Sachs Group, Inc. (The)DowngradeBuy -> NeutralView Rating Details
6/14/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformView Rating Details
6/14/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$14.00 -> $2.00View Rating Details
5/19/2015Janney Montgomery ScottReiterated RatingBuy$20.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
11/3/2016Q3($0.43)($0.33)ViewN/AView Earnings Details
8/9/2016Q2($0.38)($0.46)ViewN/AView Earnings Details
5/2/2016($0.41)($0.37)ViewN/AView Earnings Details
3/7/2016Q416($0.45)ViewN/AView Earnings Details
10/29/2015($0.51)($0.35)ViewN/AView Earnings Details
8/4/2015($0.51)($0.37)ViewN/AView Earnings Details
5/11/2015($0.47)($0.50)ViewN/AView Earnings Details
3/12/2015($0.39)$0.62ViewN/AView Earnings Details
11/13/2014Q3 14($0.50)($0.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)
Current Year EPS Consensus Estimate: $-1.48 EPS
Next Year EPS Consensus Estimate: $-1.21 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.40)($0.37)($0.39)
Q2 20162($0.40)($0.39)($0.40)
Q3 20162($0.41)($0.39)($0.40)
Q4 20162($0.45)($0.39)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Marinus Pharmaceuticals (NASDAQ:MRNS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 30.88%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/20/2016Anand MehraMajor ShareholderSell750,683$1.39$1,043,449.37View SEC Filing  
8/8/2016Vii Lp CanaanMajor ShareholderSell149,154$1.50$223,731.00View SEC Filing  
8/4/2016Vii Lp CanaanMajor ShareholderSell145,583$1.50$218,374.50View SEC Filing  
7/29/2016Vii Lp CanaanMajor ShareholderSell24,540$1.71$41,963.40View SEC Filing  
7/27/2016Vii Lp CanaanMajor ShareholderSell20,589$1.81$37,266.09View SEC Filing  
7/26/2016Vii Lp CanaanMajor ShareholderSell20,380$1.81$36,887.80View SEC Filing  
7/25/2016Vii Lp CanaanMajor ShareholderSell270,750$1.90$514,425.00View SEC Filing  
4/21/2015Gail M FarfelInsiderSell30,000$9.48$284,400.00View SEC Filing  
8/5/2014Domain Partners Vi, L.P.Major ShareholderBuy419,744$8.00$3,357,952.00View SEC Filing  
8/5/2014Stephen M BlochDirectorBuy625,000$8.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Marinus Pharmaceuticals (NASDAQ:MRNS)
DateHeadline
News IconMarket Focus- Increased Volatility Recorded on Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Aiken Advocate (NASDAQ:MRNS)
aikenadvocate.com - February 22 at 6:46 PM
News IconStocks to Lookout for: Parker-Hannifin Corporation (NYSE:PH), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - The Newburgh Press (NASDAQ:MRNS)
newburghpress.com - February 21 at 6:16 PM
News IconAnalysts Peer Into Their Crystal Balls For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Where Is It headed? - Winfield Review (NASDAQ:MRNS)
winfieldreview.com - February 21 at 6:16 PM
News IconStock Price of Marinus Pharmaceuticals, Inc. (MRNS) Increases ... - Highland Mirror (NASDAQ:MRNS)
www.highlandmirror.com - February 21 at 6:16 PM
News IconWhat Does The Chart For Marinus Pharmaceuticals, Inc. (MRNS) Tell Us Presently? - NY Stock News (NASDAQ:MRNS)
nystocknews.com - February 19 at 9:51 AM
kcregister.com logoMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced publication of preclinical data of Neuropharmacology (NASDAQ:MRNS)
www.kcregister.com - February 17 at 4:14 PM
investornewswire.com logoMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:MRNS)
www.investornewswire.com - February 16 at 6:15 PM
News IconSignal Watch: Checking the Numbers for Marinus Pharmaceuticals Inc (MRNS) - Rives Journal (NASDAQ:MRNS)
rivesjournal.com - February 14 at 8:15 PM
streetinsider.com logoMarinus Pharma (MRNS) Says Study Shows Ganaxolone Reduces ... - StreetInsider.com (NASDAQ:MRNS)
www.streetinsider.com - February 14 at 8:15 PM
finance.yahoo.com logoGanaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model (NASDAQ:MRNS)
finance.yahoo.com - February 14 at 8:15 PM
finance.yahoo.com logo7:31 am Marinus Pharmaceuticals announces the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAa, ganaxolone ameliorates many of the behavioral abnormalities in (NASDAQ:MRNS)
finance.yahoo.com - February 14 at 8:15 PM
News IconCompany Watch: Checking the Numbers for Marinus ... - Piedmont Register (NASDAQ:MRNS)
piedmontregister.com - February 9 at 5:36 AM
biz.yahoo.com logoMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E (NASDAQ:MRNS)
biz.yahoo.com - February 8 at 7:32 PM
News IconZooming in on Stock Levels: Marinus Pharmaceuticals Inc (MRNS) - Rives Journal (NASDAQ:MRNS)
rivesjournal.com - February 8 at 12:59 AM
4-traders.com logoMarinus Pharmaceuticals : Appoints Michael R. Dougherty to its Board of Directors (NASDAQ:MRNS)
www.4-traders.com - February 3 at 12:34 AM
News IconInvestor Sphere: Keeping an Eye on Levels for Marinus Pharmaceuticals Inc (MRNS) - Sherwood Daily (NASDAQ:MRNS)
sherwooddaily.com - February 2 at 7:31 PM
News IconTechnical Study: Following Indicators for Marinus Pharmaceuticals Inc (MRNS) - Sherwood Daily (NASDAQ:MRNS)
sherwooddaily.com - February 1 at 7:43 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)? - Wall Street Beacon (NASDAQ:MRNS)
wsbeacon.com - February 1 at 7:43 PM
globenewswire.com logoMarinus Appoints Michael R. Dougherty to its Board of Directors - GlobeNewswire (press release) (NASDAQ:MRNS)
globenewswire.com - February 1 at 7:43 PM
finance.yahoo.com logoMarinus Appoints Michael R. Dougherty to its Board of Directors (NASDAQ:MRNS)
finance.yahoo.com - February 1 at 7:43 PM
News IconWhat are Analysts Expecting for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Earnings? - Aiken Advocate (NASDAQ:MRNS)
aikenadvocate.com - February 1 at 12:33 AM
News IconAre These Shares a Bargain: Update on Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Prospect Journal (NASDAQ:MRNS)
prospectjournal.com - February 1 at 12:33 AM
News IconMarinus Pharmaceuticals, Inc. (MRNS) Valuation According To Analysts (NASDAQ:MRNS)
myhealthbowl.com - January 27 at 3:17 AM
News IconEarnings in Full Force, Analysts Take Aim at Marinus ... - Wall Street Beacon (NASDAQ:MRNS)
wsbeacon.com - January 26 at 10:17 PM
istreetwire.com logoStocks in Review: Amtech Systems, Inc. (ASYS), Marinus Pharmaceuticals, Inc. (MRNS), Gentex Corporation (GNTX) - iStreetWire (NASDAQ:MRNS)
istreetwire.com - January 26 at 10:17 PM
News IconTechnical Action Update on Shares of Marinus Pharmaceuticals Inc (MRNS) - Sherwood Daily (NASDAQ:MRNS)
sherwooddaily.com - January 26 at 10:17 PM
News IconCan This Stock Price Climb The Ladder: Marinus Pharmaceuticals ... - Prospect Journal (NASDAQ:MRNS)
prospectjournal.com - January 26 at 10:17 PM
News IconStock Seesawing as Volatility Sweeps in on Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Wall Street Beacon (NASDAQ:MRNS)
wsbeacon.com - January 26 at 10:17 PM
News IconMost Active Volume Stock: Marinus Pharmaceuticals Inc (MRNS) (NASDAQ:MRNS)
thecelebritytruth.com - January 25 at 8:10 PM
proactiveinvestors.co.uk logoMarinus Pharmaceuticals Inc shares soar on early study results (NASDAQ:MRNS)
www.proactiveinvestors.co.uk - January 25 at 3:38 AM
streetinsider.com logoForm 8-K MARINUS PHARMACEUTICALS For: Jan 23 (NASDAQ:MRNS)
www.streetinsider.com - January 24 at 7:23 PM
nasdaq.com logoMid-Day Market Update: Marinus Pharma Surges Following ... - Nasdaq (NASDAQ:MRNS)
www.nasdaq.com - January 24 at 5:01 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Halliburton, Marinus Pharma - Nasdaq (NASDAQ:MRNS)
www.nasdaq.com - January 24 at 5:01 AM
News IconPriming The Pump: Stock Volatility Spotted in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Wall Street Beacon (NASDAQ:MRNS)
wsbeacon.com - January 24 at 5:01 AM
News IconStock Going Gangbusters Mid-Session: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Wall Street Beacon (NASDAQ:MRNS)
wsbeacon.com - January 24 at 5:01 AM
streetinsider.com logoMarinus Pharma (MRNS) Announes Positive Preliminary Data from CDKL5 Patients Enrolled in Ongoing Phase 2 ... - StreetInsider.com (NASDAQ:MRNS)
www.streetinsider.com - January 24 at 5:01 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, auto parts retailers, Sprint (NASDAQ:MRNS)
m.nasdaq.com - January 23 at 6:58 PM
4-traders.com logoMarinus Pharmaceuticals : MRNS) Leaps on Study Update (NASDAQ:MRNS)
www.4-traders.com - January 23 at 6:58 PM
investopedia.com logoMarinus Spikes on Positive Seizure Drug Data (MRNS) (NASDAQ:MRNS)
www.investopedia.com - January 23 at 6:58 PM
marketwatch.com logoMarinus Pharma stock surges 49% on positive mid-stage data for pediatric epilepsy drug (NASDAQ:MRNS)
www.marketwatch.com - January 23 at 6:58 PM
investopedia.com logoMarinus Anti-Seizure Drug Did Well in Early Trial (NASDAQ:MRNS)
www.investopedia.com - January 23 at 6:58 PM
finance.yahoo.com logoWhy This Seizure Drug Matters So Much for Marinus Pharma (NASDAQ:MRNS)
finance.yahoo.com - January 23 at 6:57 PM
us.rd.yahoo.com logoMarinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder (NASDAQ:MRNS)
us.rd.yahoo.com - January 23 at 10:06 AM
News IconAmplified Volatility Spotted in Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Wall Street Beacon (NASDAQ:MRNS)
wsbeacon.com - January 20 at 7:26 PM
News IconSorting Out the Technicals on Shares of Marinus Pharmaceuticals Inc (MRNS) - Sherwood Daily (NASDAQ:MRNS)
sherwooddaily.com - January 20 at 2:21 AM
News IconAre Institutions Trimming Down Their Positions In Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Wall Street Beacon (NASDAQ:MRNS)
wsbeacon.com - January 20 at 2:21 AM
biz.yahoo.com logoMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MRNS)
biz.yahoo.com - January 19 at 9:20 PM
News IconA Look at this Riveting Stock: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Prospect Journal (NASDAQ:MRNS)
prospectjournal.com - January 18 at 6:56 AM
News IconWatching the Charts on Shares of Marinus Pharmaceuticals Inc (MRNS) - Sherwood Daily (NASDAQ:MRNS)
sherwooddaily.com - January 17 at 7:00 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Wall Street Beacon (NASDAQ:MRNS)
wsbeacon.com - January 16 at 5:46 AM

Social

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Where is Marinus Pharmaceuticals' stock going? Where will Marinus Pharmaceuticals' stock price be in 2017?

5 analysts have issued twelve-month price objectives for Marinus Pharmaceuticals' shares. Their forecasts range from $2.00 to $17.00. On average, they expect Marinus Pharmaceuticals' share price to reach $9.50 in the next twelve months.

When will Marinus Pharmaceuticals announce their earnings?

Marinus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about Marinus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:

  • According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (1/4/2017)

  • Oppenheimer Holdings, Inc. analysts commented, "As we only took into account the adult epilepsy indication in our valuation, and left any contribution from the other programs as upside, we are moving to a Perform rating," (6/14/2016)

Who owns Marinus Pharmaceuticals stock?

Marinus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (11.07%) and Orbimed Advisors LLC (2.88%). Company insiders that own Marinus Pharmaceuticals stock include Anand Mehra, Gail M Farfel and Vii Lp Canaan.

How do I buy Marinus Pharmaceuticals stock?

Shares of Marinus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Marinus Pharmaceuticals stock cost?

One share of Marinus Pharmaceuticals stock can currently be purchased for approximately $1.37.

Marinus Pharmaceuticals (NASDAQ:MRNS) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Earnings History Chart

Earnings by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Dividend History Chart

Dividend Payments by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Last Updated on 2/26/2017 by MarketBeat.com Staff